Hormonal
SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) and GLP-1 receptor agonists (e.g., liraglutide) provide robust cardiorenal protection in type 2 diabetes, reducing cardiovascular mortality, heart failure hospitalizations, and kidney disease progression independent of glycemic control.
If you have Type 2 Diabetes and heart or kidney issues, standard sugar-lowering drugs may not be enough. Newer classes of drugs (SGLT2 inhibitors like Jardiance/Farxiga and GLP-1 agonists like Ozempic/Victoza) are proven to significantly reduce the risk of heart attacks, heart failure hospitalizations, and kidney failure. These benefits occur even if your blood sugar numbers don't change drastically, so discuss these specific organ-protective benefits with your doctor.
novel agents such as the sodium-glucose cotransporter type 2 (SGLT2) inhibitors and glucagon-like peptide receptor agonists (GLP-1 RAs) demonstrating robust evidence in cardiorenal protection... The significant cardiovascular risk reduction observed in these landmark trials established a new paradigm in T2DM management, shifting the traditional glucose-centric approach to one that emphasizes cardiovascular risk reduction.
Why this rating
Based on multiple large-scale Cardiovascular Outcome Trials (CVOTs) like EMPA-REG, LEADER, DAPA-HF, and CREDENCE.
Source
Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future
Ying Jie Chee et al. · Biomedicines · 2024
DOI 10.3390/biomedicines12071386
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →